MX384569B - Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina - Google Patents

Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina

Info

Publication number
MX384569B
MX384569B MX2018008653A MX2018008653A MX384569B MX 384569 B MX384569 B MX 384569B MX 2018008653 A MX2018008653 A MX 2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A MX 384569 B MX384569 B MX 384569B
Authority
MX
Mexico
Prior art keywords
azepine
pyrido
dopamine
tetrahydro
ligands
Prior art date
Application number
MX2018008653A
Other languages
English (en)
Other versions
MX2018008653A (es
Inventor
Bethany Lyn Kormos
Jaclyn Louise Henderson
Jamison Bryce Tuttle
Joseph Michael Young
Joseph Walter Tucker
Nandini Chaturbhai Patel
Patrick Robert Verhoest
Simone Sciabola
Thomas Allen Chappie
Travis T Wager
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018008653A publication Critical patent/MX2018008653A/es
Publication of MX384569B publication Critical patent/MX384569B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula I: (ver formula) y sales farmacéuticamente aceptables de los mismos en donde las variables R1, R2, R3, R4, R5, a y A son como se definen en la presente; procesos para la preparación de; intermedios utilizados en la preparación de; y composiciones que contienen dichos compuestos o sales, y sus usos para tratar trastornos mediados por D3 (o asociados con D3) que incluyen, por ejemplo, adicción a sustancias, abuso de sustancias, esquizofrenia (por ejemplo, sus síntomas cognitivos), deterioro cognitivo (por ejemplo, deterioro cognitivo asociado con esquizofrenia, AD o PD), enfermedad de Parkinson, manía, ansiedad, trastornos del control de impulsos, trastornos sexuales y depresión.
MX2018008653A 2016-01-15 2017-01-09 Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina MX384569B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662279037P 2016-01-15 2016-01-15
PCT/IB2017/050094 WO2017122116A1 (en) 2016-01-15 2017-01-09 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS

Publications (2)

Publication Number Publication Date
MX2018008653A MX2018008653A (es) 2018-12-10
MX384569B true MX384569B (es) 2025-03-14

Family

ID=57838441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008653A MX384569B (es) 2016-01-15 2017-01-09 Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina

Country Status (16)

Country Link
US (2) US10590128B2 (es)
EP (1) EP3402796B1 (es)
JP (1) JP6929857B2 (es)
KR (1) KR102206321B1 (es)
CN (1) CN108884093B (es)
AU (1) AU2017208119B2 (es)
BR (1) BR112018013955B1 (es)
CA (1) CA3011201C (es)
ES (1) ES2837018T3 (es)
IL (1) IL260298B (es)
MX (1) MX384569B (es)
RU (1) RU2712455C1 (es)
SG (1) SG11201805202VA (es)
TW (1) TWI633104B (es)
WO (1) WO2017122116A1 (es)
ZA (1) ZA201803776B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6929857B2 (ja) 2016-01-15 2021-09-01 ファイザー・インク 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CA3089498A1 (en) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect
CN108997287B (zh) * 2018-07-23 2021-12-28 陕西师范大学 以四氟硼酸的离子液体为氟源催化合成4-氟代四氢吡喃衍生物的方法
CN109608451A (zh) * 2018-12-17 2019-04-12 上海药明康德新药开发有限公司 一种2-氧亚基-吡啶并[2,3-d]氮杂卓-7(2H)-甲酸叔丁酯合成方法
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20050090485A1 (en) * 2002-02-13 2005-04-28 Bromidge Steven M. 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
WO2003068732A2 (en) 2002-02-13 2003-08-21 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
GB0412314D0 (en) 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EA200701856A1 (ru) 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
WO2007028132A2 (en) 2005-09-01 2007-03-08 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
WO2008009125A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
GB0619176D0 (en) 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
EP2179385A2 (en) 2007-07-09 2010-04-28 Technion Research & Development Foundation Ltd. Routing methods for multiple geographical entities
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
CN101712675B (zh) 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
PE20160664A1 (es) * 2013-06-27 2016-07-09 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
EP3021673A1 (en) 2013-07-17 2016-05-25 Bayer CropScience Aktiengesellschaft Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties
JP6929857B2 (ja) 2016-01-15 2021-09-01 ファイザー・インク 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド

Also Published As

Publication number Publication date
EP3402796B1 (en) 2020-11-18
US20190047997A1 (en) 2019-02-14
IL260298B (en) 2021-07-29
US10590128B2 (en) 2020-03-17
TWI633104B (zh) 2018-08-21
RU2712455C1 (ru) 2020-01-29
CN108884093A (zh) 2018-11-23
US11390623B2 (en) 2022-07-19
JP2019501930A (ja) 2019-01-24
BR112018013955A2 (pt) 2018-12-11
CA3011201C (en) 2020-09-22
KR102206321B1 (ko) 2021-01-21
CN108884093B (zh) 2021-07-09
ES2837018T3 (es) 2021-06-29
BR112018013955B1 (pt) 2024-01-16
MX2018008653A (es) 2018-12-10
WO2017122116A1 (en) 2017-07-20
KR20180100432A (ko) 2018-09-10
JP6929857B2 (ja) 2021-09-01
IL260298A (en) 2018-08-30
ZA201803776B (en) 2020-09-30
US20200157098A1 (en) 2020-05-21
AU2017208119A1 (en) 2018-06-28
AU2017208119B2 (en) 2019-11-07
CA3011201A1 (en) 2017-07-20
SG11201805202VA (en) 2018-07-30
EP3402796A1 (en) 2018-11-21
TW201736367A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
MX2018008653A (es) Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
MX382599B (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina.
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
GT201300206A (es) Imidazo(5,1-f)(1,2,4)triazinas para el tratamiento de transtornos neurológicos
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
UY35129A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
MX2015011618A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso.
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2015000009A (es) Antagonistas del receptor de 5-ht3
SV2016005306A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
UY36218A (es) “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
CL2015000559A1 (es) Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
SV2016005305A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.